These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 6965464)
1. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Uchida A; Hoshino T Cancer; 1980 Feb; 45(3):476-83. PubMed ID: 6965464 [TBL] [Abstract][Full Text] [Related]
2. [Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy]. Sekizuka H; Noro K; Haruyama S; Kiribuchi Y; Hayashi F Gan No Rinsho; 1985 Sep; 31(11):1381-6. PubMed ID: 3877822 [TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients]. Yagi Y; Yagi S; Ichiki H Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349 [TBL] [Abstract][Full Text] [Related]
4. Changes in immunological parameters in lung cancer patients undergoing immunotherapy with streptococcal preparation OK-432. Watanabe Y; Shimizu J; Hashizume Y; Tsunamura Y; Yamada T; Iwa T; Sakai S; Murayama T; Koshimura S; Saito M Biotherapy; 1990; 2(3):235-45. PubMed ID: 2206775 [TBL] [Abstract][Full Text] [Related]
5. [The effect of OK-432 in the treatment of primary lung cancer]. Kishimoto T; Okada K Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430 [TBL] [Abstract][Full Text] [Related]
6. Correlation between lymphocyte responsiveness to mitogens and results of chemo-immunotherapy in patients with advanced cancer. Toge T; Yamada Y; Ikeda H; Niimoto M; Hattori T Gan; 1979 Oct; 70(5):699-703. PubMed ID: 520761 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients. Yagi Y; Yagi S Int J Immunopharmacol; 1988; 10(4):451-61. PubMed ID: 3049405 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of streptococcal preparation OK-432 for gastric cancer patients--comparison between intradermal and intramuscular injection. Hanaue H; Kurosawa T; Yoshizaki S; Shikata J Jpn J Surg; 1984 May; 14(3):191-7. PubMed ID: 6611437 [TBL] [Abstract][Full Text] [Related]
9. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment. Yoshimura Y; Oka M; Harada T; Inou Y; Saito H; Odagawa T; Matsumoto K J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382 [TBL] [Abstract][Full Text] [Related]
10. Effect of immunochemotherapy on lymphocyte response of patients with gastrointestinal cancer. Mashiba H; Yoshinaga H; Matsunaga K; Gojobori M; Furusawa M J Surg Oncol; 1979; 12(3):275-9. PubMed ID: 502567 [TBL] [Abstract][Full Text] [Related]
11. [Su-polysaccharide skin test and immunotherapy with OK-432 in postoperative gastric cancer--the effect of a splenectomy]. Saito H; Kikkawa H; Bando H; Sakatoku M; Hirano M; Tatsuzawa T Gan No Rinsho; 1988 Nov; 34(14):1965-8. PubMed ID: 3204664 [TBL] [Abstract][Full Text] [Related]
12. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma]. Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399 [TBL] [Abstract][Full Text] [Related]
13. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy. Uchida A; Hoshino T Int J Cancer; 1980 Oct; 26(4):401-4. PubMed ID: 6454666 [TBL] [Abstract][Full Text] [Related]
14. [Role of immune skin reactions in progressive lung cancer during the administration of OK-432--relation to reactions to DNCB, PPD and Su-PS]. Katada H; Nishikawa K; Yoneda T; Kitamura H; Nakajima A; Mikami R Gan To Kagaku Ryoho; 1987 Jan; 14(1):61-70. PubMed ID: 3026256 [TBL] [Abstract][Full Text] [Related]
15. [The Su-polysaccharide skin test in lung cancer]. Harada J; Horiguchi T; Oki K; Miyamoto H; Osada T Gan To Kagaku Ryoho; 1987 Sep; 14(9):2697-702. PubMed ID: 3307634 [TBL] [Abstract][Full Text] [Related]
16. Immunochemotherapy in human hepatocellular carcinoma using the streptococcal agent OK-432. Imaoka S; Sasaki Y; Ishikawa O; Ouhigashi H; Koyama H; Iwanaga T; Ishiguro S J Clin Oncol; 1986 Nov; 4(11):1645-51. PubMed ID: 2430071 [TBL] [Abstract][Full Text] [Related]
17. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer]. Kikkawa N; Sasai H; Kawahara T Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group. Cancer; 1987 Nov; 60(10):2394-402. PubMed ID: 2889522 [TBL] [Abstract][Full Text] [Related]
19. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis]. Horiuchi M; Sato K; Nakarai I; Shinoda A Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937 [TBL] [Abstract][Full Text] [Related]
20. Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients. Fujimoto S; Takahashi M; Minami T; Ishigami H; Miyazaki M; Itoh K Jpn J Surg; 1979 Sep; 9(3):190-6. PubMed ID: 470251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]